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Abstract
The colon adenocarcinoma cell line CC531 was adopted as a model for immunotherapeutical treatment of experimental
colorectal metastases in a syngeneic rat model. We studied the presence and localization of T and natural killer cells, vessels
and matrix proteins in in vivo growing CC531 tumours by immunohistochemistry. CC531 tumours were induced either in
the lungs by injecting CC531 tumour cells into a tail vein or in the liver by injection of CC531 tumour cells under the liver
capsule or into a mesenteric vein. All 3 tumour types were composed of islets of tightly apposed tumour cells surrounded
by abundantly present tumour-stroma which contained tumour vessels and matrix proteins. Some of these matrix proteins,
especially laminin and collagen IV formed a basal membrane-like structure around the tumour nodules. This structure was
most pronounced in mesenteric vein-induced liver tumours and less prominent in subcapsular-induced liver tumours and
tail vein-induced lung tumours. Tumour-infiltrating lymphocytes of both T and natural killer cell origin were found in the
tumours, but predominantly in the tumour stroma, separated from the islets of tumour cells by the basal membrane-like
structure. We hypothesize that the matrix proteins of these tumours play an ambivalent role: they may provide a substratum
for migration of effector cells into the tumour stroma but may also provide a barrier preventing direct contact between
tumour target cells and immune effector cells.
Abbreviations: BM – basal membrane; BSA – bovine serum albumin; CM – complete medium; DAB – di-amino carbazole;
HBSS – Hanks’ Balanced Salt Solution; HRP – horse radish peroxidase; IL – interleukin; (A-)NK – (activated) natural killer;
PBS – phosphate buffered saline; SCI – subcapsular-induced; MVI – mesenteric vein-induced; RT – room temperature; TVI
– tail vein induced
Introduction
Treatment of metastases derived from colorectal carcinomas
still forms a major therapeutic challenge in the clinic. Im-
munotherapy may provide new methods to combat these
metastases but extensive pre-clinical analysis is necessary
for an optimal translation to the patient. The chemically
induced rat colon adenocarcinoma CC531 [24], which is
syngeneic with the Wag rat strain has been shown to share
many characteristics with human colon adenocarcinomas
[32] and may therefore be a useful model to test new
immunotherapeutic approaches.
We are currently investigating in our laboratory two ther-
apeutic approaches, including the use of adoptively trans-
ferred lymphocytes (i.e. T cells or natural killer (NK) cells)
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and the use of interleukin 2 (IL-2). In both approaches, the
anti-tumour effect is likely to be performed by either the
adoptively transferred cells or by endogenous effector cells.
To achieve this task, we envision that the effector cells arrive
at the tumour site via the blood stream, extravasate through
the endothelium, and then migrate via the extracellular
matrix towards the tumour cells after which tumour cell-to-
immune cell contact is established. Assuming that this series
of events is indeed necessary, the success of immunotherapy,
whether based on transfer of effector cells or administration
of cytokines, is likely to depend on the accessibility of the
malignant cells within the tumour by the effector cells. A
recent paper by Mukai and co-workers demonstrated that in-
filtration of tumours by adoptively transferred effector cells
– in this case cultured, lymph node derived T cells – may
indeed be necessary for anti-tumour effects [25].
Others and we have previously shown that the number
of effector cells that reaches a tumour is highly dependent
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on the location of the tumour and on the route of adminis-
tration of the effector cells [1, 2, 11, 22]. The accessibility
of the tumour itself is likely to depend on the extent of vas-
cularization of the tumours and the presence, composition
and localization of matrix proteins in the tumour stroma
[27]. Furthermore, the number and localization of endoge-
nous, tumour-infiltrating T-and NK cells will probably be of
importance for the therapeutic application of cytokines.
In the present study we have investigated the presence
and localization of matrix proteins, blood vessels and T
and NK cells in CC531 tumours. Liver tumours, either
subcapsularly-induced or induced by injection via a mesen-
teric vein, and lung tumours, induced by injection of tumour
cells via a lateral tail vein, were subjected to these studies.
Immunohistochemical parameters were compared in these
3 tumour types to see if tumours from the same cell line,
but differently induced, have different characteristics which
could have implications for immunotherapy.
Materials and methods
Animals
Male Wag-Rij rats, a Wistar-derived inbred strain, were pur-
chased from either Charles River (Schulzfeld, Germany)
or from Harlan (Zeist, The Netherlands) and used at 4–5
months of age, weighing approximately 260 grams. The an-
imals had free access to standard food pellets and water. All
animal experiments were approved by the local committee
for animal welfare.
Induction of liver-and lung tumours
The CC531 cell line, derived from a dimethyl hydrazine-
induced Wag rat adenocarcinoma of the colon [24] was cul-
tured in complete medium (CM) which consisted of RPMI
1640 medium supplemented with 10% (v/v) heat-inactivated
fetal bovine serum, 2 mM glutamine, 50µg/ml streptomycin
and 50 U/ml penicillin (all from Gibco, Paisley, UK). Cells
were maintained by serial passage. Tumour cells were har-
vested with a solution of 0.1% (w/v) EDTA and 0.25% (w/v)
trypsin in Hank’s Balanced Salt Solution (HBSS, supplied
by Sigma, St. Louis, Missouri, USA), washed three times in
0.9% (w/v) NaCl solution buffered with 1.4 mM phosphate
(PBS) and adjusted to a suspension containing 1.0 × 106
viable tumour cells (trypan blue exclusion test) per ml. All
surgical procedures were performed under clean but not ster-
ile conditions. The rats were anesthetized using halothane.
For the induction of liver tumours, the liver was exposed
by laparotomy using a median incision. For induction of
subcapsular-induced (SCI) liver tumours, 50 µl of tumour
cell suspension containing 50 × 103 tumour cells was in-
jected subcapsularly (4 tumours per liver) at 2 places in both
the left and right main lobes of the liver. Mesenteric vein-
induced (MVI) liver tumours were created by the injection
of 1 × 106CC531 cells via a mesenteric vein. Subcapsular
tumours were allowed to grow for 5 days and mesenteric
tumours for 10 days. For induction of CC531 lung tumours,
rats were first injected with 30 mg cyclophosphamide in
1 ml PBS into the peritoneal cavity and 1 day thereafter with
2.5 × 106 CC531 cells in 1 ml RPMI 1640 in a lateral tail
vein. Lung tumours were allowed to grow for 12 days.
Antibodies
The primary antibodies used are summarized in the follow-
ing table:
Antibody and Recognizes Species Supplier
isotype
CC52 IgG1 CC531 cells mouse 1)
3.2.3 IgG1 rat CD161A mouse 2)
R73 IgG1 rat TCRαβ mouse 3)
RECA 1 IgG1 rat endothelium mouse 4)
polyclonal collagen type I goat 5)
polyclonal collagen type III goat 5)
polyclonal collagen type IV rabbit 6)
polyclonal collagen type VI rabbit 7)
polyclonal laminin rabbit 8)
polyclonal fibronectin goat 9)
1) Own department [4, 32].
2) Own department, gift from Dr W.H. Chambers, Pittsburgh Cancer
Institute, Pittsburgh, Pennsylvania, USA [5].
3) Own department, gift from Dr Th. Hünig, University of Würzburg,
Germany [17].
4) Gift from Dr. A.M. Duijvestijn, Department of Immunology, Univer-
sity of Limburg, Maastricht, The Netherlands [8].
5) Produced by Sera-Lab, supplied by Sanbio, Uden, The Netherlands.
6) Produced by HEYL, Berlin, Germany, and supplied by Sanbio, Uden,
The Netherlands.
7) Produced by Telios, San Diego, USA, and supplied by Sanbio, Uden,
The Netherlands.
8) Produced by HEYL, Berlin, Germany, and supplied by Sanbio, Uden,
The Netherlands.
9) Produced by Sigma, St. Louis, Missouri, USA, and supplied by
Brunschwig, Amsterdam, The Netherlands.
Immunohistochemistry
Five-µm-thick cryostat (Reichert Jung 2800 Frigocut, Leica,
Nussloch, Germany) sections were cut from the snap frozen
tumour tissue. Sections were air-dried for at least 16 h at
room temperature (RT). Next, they were fixed in acetone for
10 min and washed twice in PBS. All dilutions of antibod-
ies and conjugates were performed with PBS containing 1%
(w/v) bovine serum albumin (BSA, Boehringer Mannheim,
Germany). The tissue sections were incubated for 60 min
with a previously determined optimal concentration of pro-
tein A purified primary antibody. After incubation with the
primary antibody, the sections were washed in PBS three
times for 5 min. In case of mouse primary antibodies, the
sections were incubated for 30 min with horse radish peroxi-
dase (HRP)-conjugated rabbit anti-mouse Ig (dilution 1:100)
and subsequently with HRP-conjugated swine anti-rabbit Ig
(dilution 1:50, both obtained from DAKO, Glostrup, Den-
mark) and subsequent washes in PBS. In case of rabbit or
goat polyclonal antibodies as primary antibodies, the sec-
tions were incubated with HRP-conjugated swine anti-rabbit
Ig or HRP-conjugated rabbit anti-goat Ig (dilution 1:100,
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obtained from DAKO). Visualization of immune complexes
was performed by a 10 min incubation with a di-amino car-
bazole (DAB) substrate in a buffered TRIS-HCl (pH = 7.6)
solution containing 1.8 × 10−3 % (v/v) hydrogen peroxide.
For immunohistochemical single-color stainings, the sec-
tions were counter stained using hematoxylin, dehydrated
and mounted using Pertex (Histolab, Göteborg, Sweden).
In case of double stainings, the sections were washed
twice in PBS and subsequently incubated for 30 min
with a second primary antibody. After 3 wash steps with
PBS, the sections were incubated for 30 min with either
HRP-conjugated rabbit anti-mouse Ig, with HRP-conjugated
swine anti-rabbit Ig or with HRP-conjugated rabbit anti-goat
Ig (all DAKO). The immune complexes were visualized by
a 12 min incubation step in a buffered TRIS-HCl (pH= 7.6)
solution containing per 100 ml: (1) 40 mg 4-chloro-1-
naphtol (Merck, Darmstadt, Germany) dissolved in 200 µl
di-methyl formamide (Baker B.V., Deventer, The Nether-
lands) and 300 µl ethanol (Merck); and (2) 200 µl of a 30%
(v/v) H2O2 solution (Merck). The sections were slightly
counter stained using nuclear fast red and mounted using
Kaiser’s Glycerine (Merck). Three control sections per tu-
mour were included in which either one or both primary
antibodies were omitted.
Results
Liver tumours and lung tumours: macroscopic and
microscopic anatomy
At macroscopic level, tail vein-induced (TVI) lung tumours
appeared as white nodules in the lung parenchyma. On
cross sections the tumour areas varied from approximately
0.04 mm2 to 0.12 mm2. The subcapsularly-induced (SCI)
liver tumours appeared as white nodules on the liver surface
with some scar tissue due to the needle which was used
for injection of tumour cell suspension. On cross sections,
the tumour areas were approximately 1.9 mm2. Mesenteric
vein-induced (MVI) liver tumours were randomly distrib-
uted throughout the liver parenchyma. Their sizes on cross
sections varied considerably from 0.03 mm2 to 1.8 mm2 to
large confluent areas of tumour tissue.
TVI lung tumours (Figure 1a), SCI liver tumours (Fig-
ure 1b), and MVI liver tumours (Figure 1c) showed the same
microscopic aspect: the tumours were composed of islets of
closely apposed tumour cells which were surrounded by a
stromal component. Both types of liver tumours revealed
an abundant stromal compartment whereas the TVI lung tu-
mours had a sparse stromal compartment. In all 3 tumour
types the islets of tumour cells showed a large variation
in size. In MVI liver tumours the tumour cell islets had a
glandular-like shape whereas the tumour cell islets of SCI
liver tumours and TVI lung tumours had a less regular shape.
Matrix composition
Analysis by immunohistochemistry revealed the presence of
collagen type I, III (Figures 2a, c, e), IV (Figures 2b, d,
Figure 1 Typical aspect of haematoxylin and eosin-stained sections of tail
vein-induced (TVI) lung tumours (a), subcapsularly-induced (SCI) liver
tumours (b), and mesenteric vein-induced (MVI) liver tumours (c). All
tumour types were composed of islets of closely apposed tumour cells sur-
rounded by a stromal component. Both types of liver tumours revealed an
abundant stromal compartment whereas the TVI lung tumours had a sparse
stromal compartment. The islets of tumour cells, which showed a large
variation in size in all 3 tumour types, had a glandular-like shape in MVI
liver tumours (c) whereas the tumour cell islets of TVI lung tumours (a) and
SCI liver tumours (b) had a less regular shape. Bar indicates 150 µm.
f), VI, laminin and fibronectin in all 3 tumour types, but in
the liver tumours (Figure 2c–f) a larger amount of matrix
proteins was present than in TVI lung tumours (Figures 2a,
b). Matrix proteins were present in the stromal compartment
between the tumour nodules but not in the tumour nodules
themselves. The tumour nodules were tightly surrounded by
a basal membrane (BM)-like structure consisting of laminin
and collagen IV. This was most pronounced in the MVI liver
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Figure 2 Tail vein-induced (TVI) lung tumours (a, b), subcapsular-induced (SCI) liver tumours (c, d) and MVI liver tumours (e, f) were stained for
collagen type III (a, c, e) and collagen type IV (b, d, f) using immunohistochemistry. The tumour nodules (indicated by tn) were tightly surrounded by a
BM-like structure (arrowheads) consisting of laminin (not shown) and collagen IV (b, d, f). In MVI liver tumours the BM-like structure did also contain
other matrix components like collagen type III (e, indicated by arrowheads). Bar indicates 150 µm.
tumours and less in the SCI liver tumours and TVI lung tu-
mours. In SCI liver tumours the surrounding proteins were
less continuous than in MVI tumours and in the TVI lung tu-
mours the matrix proteins surrounding the tumour nodules in
general had a thinner appearance. In MVI liver tumours the
BM-like structure did also contain other matrix components
like collagen type III (Figure 2e).
Vascularization of CC531 tumours
We studied the presence of vessels in the 3 different tumour
types. Tumour-associated vessels were stained using RECA
1 [8], a mouse monoclonal antibody which has been shown
to specifically recognize rat endothelium.
In all 3 tumour types vessels were found, as revealed
by immunohistochemistry (Figures 3a, b, c). The endothe-
lial cells were confined to the tumour stroma and were not
present in the tumour nodules which suggested that direct
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Figure 3 Sections of tail vein-induced (TVI) lung tumours (a), subcapsular-induced (SCI) (b)-and mesenteric vein-induced (MVI) (c) liver tumours were
double-stained for vessels (brown, indicated by arrowheads) and tumour cells (blue) using immunohistochemistry. Vessels were confined to the tumour
stroma and not present in the tumour nodules. Sections of SCI liver tumours (d) and MVI liver tumours (e) were double-stained for T cells (brown) and
collagen type lV (blue). T cells were predominantly located in the tumour stroma and not in direct contact with tumour cells in the tumour nodules (tn).
These effector cells were separated from the tumour nodules by a BM-like condensation of matrix proteins surrounding the tumour nodules (indicated by
arrowheads). Occasionally a T cell was found in the tumour nodules (indicated by arrows). A section of a MVI liver tumour, double-stained for T cells
(brown) and vessels (blue-stained structures, indicated by arrowheads) is shown in (f). A part of the liver parenchyma (indicated by Li) surrounding the
tumour is visible. The border between the tumour tissue and the liver parenchyma is indicated by a dotted line. Bar indicates 150 µm.
access to the tumour cells is only provided via the tumour
stroma. In lung tumours, the majority of vessels was found in
the periphery and not in the center of the tumour (Figure 3a)
but variation was observed in this pattern as some tumours
had also vessels in central parts. In SCI (Figure 3b) and MVI
liver tumours (Figure 3c), the vessels were observed both in
the periphery but also in central parts of the tumour.
Infiltration of the tumours by T and NK cells
Tumours were stained for T and NK cells in order to pre-
cisely locate these effector cells in the different tumour
types. In all 3 tumour types, both NK cells and T cells were
observed in an irregular distribution pattern. T cells, and, to
a lesser extent, NK cells clustered in large numbers at the
periphery of the tumours. The number of T cells was higher
than the number of NK cells. As can be seen in Figures 3d
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and 3e, the majority of the T cells was located in the tumour
stroma and not in direct contact with tumour cells. NK cells
showed an identical distribution pattern (not shown). Double
stainings for T or NK cells and matrix proteins showed that
these effector cells were separated from the tumour nodules
by the BM-like condensation of matrix proteins surrounding
the tumour nodules. Occasionally such an effector cell was
found in the tumour nodules (Figure 3d, e).
Double stainings for T or NK cells and endothelium re-
vealed that the majority of the lymphocytes was present in
the tumour stroma without any adjacent vessel (Figure 3f).
This demonstrated that most of the T and NK cells had
extravasated and had migrated into the tumour stroma.
Discussion
The feasibility of treatment of colorectal cancer metastases
using cytokines like IL-2 and/or the adoptive transfer of IL-2
cultured NK (A-NK) cells [11, 12] or T cells [3] will proba-
bly depend on the ability of these effector cells to reach the
tumours and to establish contact with the malignant cells.
In a recent paper, Mukai et al. demonstrated in a syngeneic
mouse lung metastasis model that the presence of adoptively
transferred T cells inside the tumour nodules is indeed a
prerequisite to attain significant anti-tumour effects [25]. If
the local presence of effector cells is indeed necessary, then
factors such as tumour vascularization and tumour content
and composition of matrix proteins may be important factors
to evaluate. Consequently, we have analyzed these factors in
the CC531 model of colon cancer.
In the CC531 model, both SCI and MVI liver tumours
and TVI lung tumours appeared to be composed of islets of
clustered tumour cells which were surrounded by matrix. In
all 3 tumour types, the matrix was shown to contain col-
lagen types I, III, IV, VI, fibronectin and laminin. In the
CC531 TVI lung tumours, less matrix was observed than
in liver tumours but it must be emphasized that the TVI
lung tumours were much smaller than both types of liver
tumours. It is therefore possible that the TVI lung tumours
will reach a more organized, glandular-like architecture with
more matrix formation after prolonged outgrowth.
Elimination of tumour cells by endogenous or adoptively
transferred effector cells is probably dependent on direct
contact between the target- and effector cells. In this context,
it is remarkable that the majority of infiltrating immune cells
– as we also showed in a previous paper [12] – was localized
in the tumour stroma and not in contact with the tumour
cells. This discrepancy might be explained in several ways.
It is possible that there is an insufficient chemotactic stim-
ulus attracting the effector cells towards the tumour cells.
Alternatively, it might be that the effector cells that reached
the tumour nodules died fast or that the tumour cells could
not be reached by the effector cells due to fibers of matrix
which tightly surrounded the tumour nodules. This BM-like
structure around the islets of tumour cells, which was previ-
ously described by Griffini et al. [10], may have limited the
accessibility of the tumour cells. On the other hand, a recent
paper by Goldfarb et al. demonstrated – in vitro but also
in vivo in our rat model – that the BM-like barrier might be
degraded by matrix metalloproteinases which were secreted
by in vitro cultured, IL-2 activated NK cells [19]. This may
suggest either that the BM-like structure was not a real ob-
stacle for the effector cells or that the amount and/or quality
of BM-degrading enzymes secreted by most of the effector
cells were insufficient.
The BM-like structure in CC531 tumours was less pro-
nounced in the SCI liver tumours and in the TVI lung
tumours than in MVI liver tumours. This implies that the lo-
cation (lung versus liver) and the method of induction (MVI
versus SCI) may influence the amount and distribution of
matrix proteins in the tumours. A similar distribution pattern
of immune cells [6, 7, 26] and matrix proteins [9, 13, 23]
like we found in our CC531 tumour model has also been
described for primary human colon tumours [9, 13, 23],
for lymph node metastases [23] and for other types of hu-
man primary malignancies [14, 16, 20, 30, 34]. If matrix
proteins influence accessibility of tumours for lymphocytes,
one would expect that susceptibility for immunotherapy of
these tumours depends – at least in part – on the anatomy of
the matrix meshwork. In that case, the differences in matrix
composition like we found in the 3 different models might be
relevant for humans. In this context, it is also interesting to
note that in previous experiments, a much higher amount of
adoptively transferred A-NK cells reached CC531 lung tu-
mours [21] than liver tumours [11]. This might be explained
by the described differences in matrix composition of these
tumour types. Alternatively, less A-NK cells may reach liver
tumours as compared to lung tumours as the majority of A-
NK cells in the CC531 liver tumour experiment seemed to
be trapped in the portal tracts which might have prevented
further migration towards the tumours.
In contrast to our approach, most attention in the liter-
ature with respect to tumour cells and matrix proteins has
been directed towards the relation between the presence of
matrix proteins in tumours and tumour cell differentiation,
tumour stage, metastasis, and prognosis. The investigations
consistently report a positive correlation between deposition
of BM-like structures and an increasing degree of differ-
entiation of the tumour cells in humans [9, 13, 23]. A
similar phenomenon has been described in a rat model [29].
Controversy exists with respect to the predictive value of
BM-like deposits for the development of metastases, tu-
mour stage and survival in humans. For instance, Hida et al.
were not able to demonstrate a correlation between the pres-
ence of this structure in the primary tumour and the stage
of the tumour [15]. Furthermore, their results suggested
that BM-preservation may promote the development of liver
metastases [15]. Other papers, however, demonstrated an
inverse correlation between the presence of a BM-like struc-
ture and the presence of metastases [9] or survival [9, 13,
28]. The precise relationship between presence of BM-like
matrix deposits and prognosis is apparently not clear. If im-
mune cells are important to eliminate developing tumours,
one would expect that the absence of a BM-like structure
surrounding the tumour cells would favor the immunologic
control.
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Another important item when considering adoptive im-
munotherapy is the number and localization of vessels in
the tumour, which is probably a prerequisite for initial
arrival of effector cells in the tumour. Experiments by Nan-
nmark and co-workers demonstrated in a syngeneic mouse
tumour model that infiltration of lung metastases by adop-
tively transferred, A-NK cells was correlated with the extent
of vascularization of these tumours [27]. This demonstrated
that the presence of vessels in the tumour may determine the
success of adoptive immunotherapy. We demonstrated in all
types of CC531 tumours the presence of vessels but solely
in the stromal part. Thus, the effector cells will not get in
contact with the malignant cells immediately following their
trans-vascular diapedesis. Rather, they must migrate across
the stroma, possibly using the stromal matrix fibers as a sub-
stratum for migration. Both in vitro and in vivo studies have
demonstrated that this may indeed be the case [12, 18, 31,
33].
The studies on distribution and composition of matrix
proteins and on vascularization which are described in this
paper are confined to a single time point of tumour growth.
It might be that during tumour progress, conditions with
regard to matrix distribution and neovascularization show
changes. This may have consequences for the accessibility
of the tumour cells for the effector cells and thus prob-
ably for anti-tumour effects. Furthermore, since CC531
liver tumours grow relatively rapidly compared to human
tumours, it might also be that the growth rate limits the
amount of effector cells and neoangiogenic vasculature that
penetrates the tumour. Therefore, it would be of interest
to perform similar studies in a model with slowly growing
adenocarcinomas of colorectal origin.
In summary, we have demonstrated that 3 different types
of in vivo growing CC531 tumours – i.e. SCI and MVI
liver tumours and TVI lung tumours – were composed of
islets of tightly apposed tumour cells surrounded by matrix
proteins. We hypothesize that these matrix proteins play an
ambivalent role: they may provide a substrate for migration
in the tumour stroma but around the tumour nodules a barrier
to establish contact with the tumour cells. Therefore, more
attention should be focused on the relation between tumour
infiltrating effector cells and the local expression of matrix
proteins. The presence of a tight BM-like structure of matrix
proteins may perhaps in part explain the failure of previous
clinical immunotherapeutical trials. In that case, the ultimate
challenge in immunotherapy may not only be the develop-
ment of cells capable of eliminating tumour cells but also to
design strategies which may overcome this matrix barrier.
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